Navigation Links
Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer

WASHINGTON, April 17, 2013 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA), announced today that it has named Paolo Baroldi , M.D., Ph.D. as its Senior Vice President and Chief Medical Officer.

Dr. Baroldi has over 30 years of clinical development experience in many therapeutic areas, including neurology and psychiatry.  He has been working in the role of acting Chief Medical Officer with Vanda since October 1, 2012.

"We welcome Paolo to Vanda and look forward to his leadership in strengthening our clinical organization," said Mihael H. Polymeropoulos , M.D., President and Chief Executive Officer of Vanda.

Dr. Baroldi previously served as the Senior Vice President and Chief Medical Officer of Vanda from July 2006 through January 2009.  He has served in senior clinical development positions at Galileo Research, Supernus Pharmaceuticals, Chiesi Farmaceutici SpA, and Novartis AG.

Dr. Baroldi holds M.D. and Ph.D. degrees from the University of Milan, Italy and is a member of the board of directors of Galileo Research. 


Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for the treatment of central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit

Company Contact

Jim Kelly
Senior Vice President  & Chief Financial Officer
Vanda Pharmaceuticals Inc.
(202) 734-3428

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Vanda Pharmaceuticals to Present at the Lazard Healthcare Conference
2. Nieuwe behandeloptie vandaag geïntroduceerd voor artsen die patiënten behandelen met veelvuldig recidiverend of refractair agressief B-cel-non-hodgkinlymfoom
3. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
4. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
5. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
6. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
7. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
(Date:9/23/2014)... Sept. 23, 2014 /PRNewswire/ - Portage Biotech Inc. ("Portage" ... PBT.U), is pleased to announce that its wholly ... two more  consultants to its team for further ... a new proprietary cell permeable peptide platform technology ... cargo into the eye. Ms. ...
(Date:9/23/2014)... Mass. (PRWEB) September 23, 2014 Cambridge ... by Semantic Web technology, was named in the recent ... Gartner, Inc. , The report details key insights ... , According to Gartner analysts Michael Shanler and ... accelerate innovation activities, expose complex relationships with scientific stakeholders, ...
(Date:9/23/2014)... , September 23, 2014 ... System Transfer     Devices  (CSTD) for ... with Taiwanese distributor MedFront Medical Technology Corporation.  Equashield,s leading CSTD ... Taiwan , China ... company continues to expand globally, and throughout the ...
(Date:9/23/2014)... 23, 2014 Marktech Optoelectronics has introduced ... violet emitters in the 280 nm wavelength range. This ... which range from 280nm to 405nm. These new devices ... as well as curing. Mark Campito, Marktech’s CEO states ... interest to manufacturers is that we offer it in ...
Breaking Biology Technology:Portage Announces New Consultants for its PPL-003 Development Programs 2Portage Announces New Consultants for its PPL-003 Development Programs 3Portage Announces New Consultants for its PPL-003 Development Programs 4Cambridge Semantics Identified in Gartner’s ‘Hype Cycle for Life Sciences 2014’ Report 2Equashield Enters Taiwan Following Expansion to Australia, Japan, China 2Marktech Introduces its New Line of Deep UV Emitters 2
... SAN FRANCISCO, Calif., Aug. 23 Monogram,Biosciences, Inc. (Nasdaq: ... CEO,and Chairman, is scheduled to present a corporate overview ... September 5, 2007,at 3:15 p.m. (Eastern Time) at the ... live audio broadcast or the subsequent archived,recording, log on ...
... (Nasdaq: KNDL ), a,leading, global full-service clinical ... 10th anniversary as a public company by,ringing the ... also marked the,anniversary with an Investor Day at ... and shareholders the company,s perspective on the,latest industry ...
... Initiative to Pursue Cures for Patients, ... controversial Human Cloning, WASHINGTON, Aug. 22 Today, a ... taxpayer funds,support cures for patients, without involving human cloning. ... statement on the new initiative, Cures Without Cloning. "I ...
Cached Biology Technology:Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007 2Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event 2Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event 3Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event 4Kendle Marks 10th Anniversary as Public Company With NASDAQ Opening Bell Ceremony and Investor Day Event 5
(Date:9/23/2014)... of Health will award funds to support the next ... to improve ways of predicting drug safety and effectiveness. ... 3-D human tissue chips and combine them into an ... the human body. Led by the National Center for ... institutions at $17 million in 2014 with additional support ...
(Date:9/23/2014)... on insects to predict how climate change will affect ... for the first time that insects, fear of their ... they grow. , "In other words, it,s less about ... shape the growth, survival and distribution of insects." says ... Arctic postdoctoral researcher at Dartmouth. , The study ...
(Date:9/23/2014)... scientists who are fighting a cyberwar against cancer finds ... powerful ally. , "Recent research has found that cancer ... system, and we studied the interplay between cancer and ... the tables on cancer," said Rice University,s Eshel Ben-Jacob, ... Early Edition of the Proceedings of the National ...
Breaking Biology News(10 mins):NIH funds next phase of Tissue Chip for Drug Screening program 2NIH funds next phase of Tissue Chip for Drug Screening program 3NIH funds next phase of Tissue Chip for Drug Screening program 4Insects' fear limits boost from climate change, Dartmouth study shows 2Immune system is key ally in cyberwar against cancer 2Immune system is key ally in cyberwar against cancer 3
... in the Journal of Proteome Research, authored by ... GmbH, Rosetta Inpharmatics LLC, CXR Biosciences Ltd, the ... synergisms and enhanced analytic power of the combination ... proprietary microarray analysis methods of Genomatix Software GmbH., ...
... The Ohio State University have demonstrated that Target Region ... preserving the important genetic diversity of ornamental flower collections. ... the most popular flowers the world. So popular, in ... 3,000 varieties of geranium in their 2004 distribution catalogue. ...
... common dietary molecules found in legumes and bran ... radiation, researchers from the University of Maryland report. ... skin cells and a skin cancer-prone mouse from ... radiation found in sunlight, the team reported today ...
Cached Biology News:'TRAP' preserves genetic properties of popular geranium 2Antioxidants could provide all-purpose radiation protection 2Antioxidants could provide all-purpose radiation protection 3
... is the simplest, easiest-to-use system ever for ... handling capabilities,into their labs, or groups in ... applications on a separate instrument. Plate-handling is ... even when you have thousands of samples., ...
... Safe Deposit Service ECACC is able to accept ... cGMP for cryo-storage. The cell lines must be ... been produced in accordance with the requirements of ... freedom from mycoplasma, bacteria or fungi. What are ...
... provides cost effective cell culture services for ... antibodies. Quality at a reasonable price is ... research or commercial product, we strive toward ... as roller bottles, hollow fiber, and bioreactor ...
... Cell Bank Service The Human Genetic ... Epstein-Barr Virus (EBV) immortalisation of human peripheral ... of lymphoblastoid cell lines (LCLs). These cell ... and expandable source of genomic DNA and ...
Biology Products: